Profile and investment
| Fund type | Open Ended Investment Company |
|---|---|
| Investment style (stocks) | Market Cap: Large Investment Style: Growth |
| Morningstar category | Large Growth |
| Launch date | 12 Nov 2001 |
| Price currency | USD |
| Domicile | United States |
| Symbol | VHCAX |
| Manager & start date | Theo Kolokotrones 01 Feb 1998 Joel Fried 01 Feb 1998 Alfred Mordecai 31 Dec 1999 M. Ansari 31 Dec 2007 James Marchetti 27 Jan 2015 |
| Pricing frequency | Daily |
|---|---|
| Total net assets | 22.49bn USD As of Mar 31 2024 |
| Share class size | 21.00bn USD As of Mar 31 2024 |
| Net expense ratio | 0.36% |
| Front end load | -- |
| Deferred load | -- |
| Maximum Redemption Fee | -- |
| Min. initial investment | 50,000.00 USD |
| Min. additional investment | 1.00 USD |
| Initial IRA | -- |
| Additional IRA | -- |
| Available for sale | United States |
More ▼
Top 5 holdings
| Top 5 holdings as a per cent of portfolio | |||
|---|---|---|---|
| 53.20% | 20.12% | 0.00% | 20.12% |
| Category average | % Net assets | % Short | % Long |
| Company | 1 year change | Portfolio weight | Long allocation |
|---|---|---|---|
| Eli Lilly and Co LLY:NYQ | +101.66% | 9.47% | |
| Amgen Inc AMGN:NSQ | +6.77% | 2.91% | |
| Biogen Inc BIIB:NSQ | -35.16% | 2.76% | |
| Microsoft Corp MSFT:NSQ | +40.19% | 2.51% | |
| Biomarin Pharmaceutical Inc BMRN:NSQ | -8.47% | 2.47% | |
| Per cent of portfolio in top 5 holdings: 20.12% |
Asset type
| US stock | 80.56% |
| Non-US stock | 14.61% |
| Cash | 4.84% |
| US bond | 0.00% |
| Non-US bond | 0.00% |
| Other | 0.00% |
Top 5 sectors
| Healthcare | 29.87% |
| Technology | 29.12% |
| Industrials | 10.65% |
| Consumer Cyclical | 9.35% |
| Financial Services | 6.74% |
| Other | 9.44% |
Top 5 regions
| United States | 80.56% |
| Eurozone | 3.63% |
| Emerging Asia | 3.36% |
| Latin America | 2.18% |
| United Kingdom | 1.66% |
| Other | 3.78% |
Sector and region weightings are calculated using only long position holdings of the portfolio.
